TRDA — Entrada Therapeutics Share News
0.000.00%
Last trade - 00:00- $171.71m
- -$51.29m
- $25.42m
Brief: Entrada Therapeutics Reports Q3 Loss Per Share Of $0.80
Brief: Entrada Therapeutics reports Q2 results
Brief: Entrada Therapeutics Collaborates With Myotonic Dystrophy Clinical Research Network
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:17 AM
NASDAQ RESUMED AT 09:48 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:43 AM
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:39 AM
Brief: Entrada Therapeutics Reports First Quarter 2022 Financial Results
Brief: Entrada Therapeutics Reports Q4, Full Year 2021 Financial Results
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM
Brief: Entrada Therapeutics To Be Added To Russell 2000 And Russell 3000 Indexes
Brief: Entrada Therapeutics Reports Third Quarter 2021 Financial Results
Brief: Entrada Therapeutics Inc Shares Open 32.5% Above IPO Price In Nasdaq Debut
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
Brief: Entrada Therapeutics Says Pricing Of Its Upsized IPO Of 9,075,000 Shares Of Common Stock At $20 Per Share